Opiant Pharmaceuticals, Inc.

NasdaqCM:OPNT 株式レポート

時価総額:US$108.8m

This company has been acquired

The company may no longer be operating, as it has been acquired. Find out why through their latest events.

このページの翻訳は実験的なもので、現在開発中です。お待ちしております

Opiant Pharmaceuticals バランスシートの健全性

財務の健全性 基準チェック /56

Opiant Pharmaceuticalsの総株主資本は$20.5M 、総負債は$13.8Mで、負債比率は67.1%となります。総資産と総負債はそれぞれ$42.0Mと$21.4Mです。

主要情報

67.1%

負債資本比率

US$13.76m

負債

インタレスト・カバレッジ・レシオn/a
現金US$35.38m
エクイティUS$20.50m
負債合計US$21.45m
総資産US$41.95m

財務の健全性に関する最新情報

Recent updates

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Aug 13
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Analysts Just Slashed This Year's Estimates

Opiant awarded additional $2.1M from BARDA for its nasal opioid overdose treatment

Aug 08

Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Aug 05
Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Shares Could Be 47% Below Their Intrinsic Value Estimate

Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Mar 21
Analysts Just Made A Major Revision To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Revenue Forecasts

Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

Nov 19
Opiant Pharmaceuticals (NASDAQ:OPNT) Is Posting Healthy Earnings, But It Is Not All Good News

These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Nov 17
These 4 Measures Indicate That Opiant Pharmaceuticals (NASDAQ:OPNT) Is Using Debt Reasonably Well

Opiant Pharmaceuticals: Assessing Recent Insider Buying

Sep 19

Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Aug 07
Party Time: Brokers Just Made Major Increases To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Earnings Forecasts

Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

Jun 09
Increases to CEO Compensation Might Be Put On Hold For Now at Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT)

The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

Mar 06
The Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Yearly Results Are Out And Analysts Have Published New Forecasts

News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Mar 05
News Flash: Analysts Just Made A Substantial Upgrade To Their Opiant Pharmaceuticals, Inc. (NASDAQ:OPNT) Forecasts

Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Jan 27
Opiant Pharmaceuticals'(NASDAQ:OPNT) Share Price Is Down 41% Over The Past Three Years.

Opiant Pharma secures additional BARDA grant of $3.5M for OPNT003

Dec 14

Opiant Pharmaceuticals receives $50M in convertible debt financing

Dec 10

財務状況分析

短期負債: OPNTの 短期資産 ( $38.5M ) が 短期負債 ( $7.0M ) を超えています。

長期負債: OPNTの短期資産 ( $38.5M ) が 長期負債 ( $14.4M ) を上回っています。


デット・ツー・エクイティの歴史と分析

負債レベル: OPNT総負債よりも多くの現金を保有しています。

負債の削減: OPNTの負債対資本比率は、過去 5 年間で0%から67.1%に増加しました。


貸借対照表


キャッシュ・ランウェイ分析

過去に平均して赤字であった企業については、少なくとも1年間のキャッシュ・ランウェイがあるかどうかを評価する。

安定したキャッシュランウェイ: OPNTは、現在の フリーキャッシュフロー に基づき、1 年以上にわたって十分な キャッシュランウェイ を有しています。

キャッシュランウェイの予測: OPNTは、フリー キャッシュ フローが毎年27.7 % の歴史的率で減少し続ける場合、 1.2年間十分なキャッシュ ランウェイを有しています。


健全な企業の発掘